Heartsciences Inc. Announces New Compensation Plan with Stock Options and RSUs for Executives and Directors

Reuters07-14

Heartsciences Inc. Announces New Compensation Plan with Stock Options and RSUs for Executives and Directors

Heartsciences Inc. has announced new compensation terms for its executive officers and non-employee directors, effective July 9, 2025. The company's Compensation Committee approved stock option awards for executive officers, including 275,000 options for CEO Andrew Simpson, 225,000 for COO Mark Hilz, and 25,000 for CFO Danielle Watson. These options, with an exercise price of $4.37 per share, will vest over three years and could accelerate upon FDA clearance of the MyoVista Device or MyoVista Insights platform. Additionally, restricted stock unit (RSU) awards were granted to Simpson and Hilz, which will vest immediately upon certain milestones, including FDA clearance or a Change of Control. Non-employee directors Brian Szymczak, Bruce Brent, and David R. Wells received 25,000 stock options each, vesting quarterly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-063491), on July 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2551361181?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-14 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551361181","market":"nz","top_or_hot":-1,"title":"Heartsciences Inc. Announces New Compensation Plan with Stock Options and RSUs for Executives and Directors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Heartsciences Inc. Announces New Compensation Plan with Stock Options and RSUs for Executives and Directors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Heartsciences Inc. has announced new compensation terms for its executive officers and non-employee directors, effective July 9, 2025. The company's Compensation Committee approved stock option awards for executive officers, including 275,000 options for CEO Andrew Simpson, 225,000 for COO Mark Hilz, and 25,000 for CFO Danielle Watson. These options, with an exercise price of $4.37 per share, will vest over three years and could accelerate upon FDA clearance of the MyoVista Device or MyoVista Insights platform. Additionally, restricted stock unit (RSU) awards were granted to Simpson and Hilz, which will vest immediately upon certain milestones, including FDA clearance or a Change of Control. Non-employee directors Brian Szymczak, Bruce Brent, and David R. Wells received 25,000 stock options each, vesting quarterly.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-063491), on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Heartsciences Inc. Announces New Compensation Plan with Stock Options and RSUs for Executives and Directors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHeartsciences Inc. Announces New Compensation Plan with Stock Options and RSUs for Executives and Directors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-14 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Heartsciences Inc. Announces New Compensation Plan with Stock Options and RSUs for Executives and Directors\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Heartsciences Inc. has announced new compensation terms for its executive officers and non-employee directors, effective July 9, 2025. The company's Compensation Committee approved stock option awards for executive officers, including 275,000 options for CEO Andrew Simpson, 225,000 for COO Mark Hilz, and 25,000 for CFO Danielle Watson. These options, with an exercise price of $4.37 per share, will vest over three years and could accelerate upon FDA clearance of the MyoVista Device or MyoVista Insights platform. Additionally, restricted stock unit (RSU) awards were granted to Simpson and Hilz, which will vest immediately upon certain milestones, including FDA clearance or a Change of Control. Non-employee directors Brian Szymczak, Bruce Brent, and David R. Wells received 25,000 stock options each, vesting quarterly.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-063491), on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL23hxPT:1","article_id":"2551361181","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551361181","pubTimestamp":1752498128,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Heartsciences Inc. has announced new compensation terms for its executive officers and non-employee directors, effective July 9, 2025. The company's Compensation Committee approved stock option awards for executive officers, including 275,000 options for CEO Andrew Simpson, 225,000 for COO Mark Hilz, and 25,000 for CFO Danielle Watson. These options, with an exercise price of $4.37 per share, will vest over three years and could accelerate upon FDA clearance of the MyoVista Device or MyoVista Insights platform. Additionally, restricted stock unit  awards were granted to Simpson and Hilz, which will vest immediately upon certain milestones, including FDA clearance or a Change of Control. Non-employee directors Brian Szymczak, Bruce Brent, and David R. Wells received 25,000 stock options each, vesting quarterly.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","HSCS":"HeartSciences Inc"},"translate_title":"Heartsciences Inc.宣布为高管和董事提供股票期权和受限制股份单位的新薪酬计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HSCS":0.9},"content_text":"Heartsciences Inc. Announces New Compensation Plan with Stock Options and RSUs for Executives and Directors\n    \n\n        Heartsciences Inc. has announced new compensation terms for its executive officers and non-employee directors, effective July 9, 2025. The company's Compensation Committee approved stock option awards for executive officers, including 275,000 options for CEO Andrew Simpson, 225,000 for COO Mark Hilz, and 25,000 for CFO Danielle Watson. These options, with an exercise price of $4.37 per share, will vest over three years and could accelerate upon FDA clearance of the MyoVista Device or MyoVista Insights platform. Additionally, restricted stock unit (RSU) awards were granted to Simpson and Hilz, which will vest immediately upon certain milestones, including FDA clearance or a Change of Control. Non-employee directors Brian Szymczak, Bruce Brent, and David R. Wells received 25,000 stock options each, vesting quarterly.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heartsciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-063491), on July 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551361181","isCrawlerRequest":true}